Brief: Longboard Pharmaceuticals Posts FY Net Loss Of $27.8 Mln
03/03/2022 21:44
March 3 (Reuters) - Longboard Pharmaceuticals Inc LBPH.O :
* LONGBOARD PHARMACEUTICALS PROVIDES CORPORATE UPDATE
AND REPORTS
FULL YEAR 2021 FINANCIAL RESULTS
* LONGBOARD PHARMACEUTICALS INC - LP659 IND SUBMISSION
REMAINS ON
TRACK FOR SECOND HALF OF 2022
* LONGBOARD PHARMACEUTICALS INC - CASH POSITION EXPECTED TO
SUPPORT OPERATIONS INTO 2024 BASED ON CURRENT BUSINESS PLAN
* LONGBOARD PHARMACEUTICALS INC - FY NET LOSS $27.8 MILLION
VERSUS
LOSS $14.4 MILLION
Source text for Eikon: ID:nGNX8csQtD
Further company coverage: LBPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Longboard Pharmaceuticals
See all newsBrief: Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin In Developmental And Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Deals of the day-Mergers and acquisitions